Phosphomannomutase 2 deficiency (Q94026): Difference between revisions
From determinar.ia.br - Determine suas informações
Changed an Item |
Changed an Item |
||||||||||||||
| Property / Collection date | |||||||||||||||
15 August 2026
| |||||||||||||||
| Property / Collection date: 15 August 2026 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Latest revision as of 09:08, 16 August 2026
Congenital disorder of glycosylation type 1a (CDG-Ia) is the most frequent form of CDG syndrome and is characterised by highly variable clinical manifestations that may include feeding problems, vomiting, and diarrhea with failure to thrive in infants, and severe encephalopathy with axial hypotonia, abnormal eye movement, marked psychomotor retardation, peripheral neuropathy, cerebellar hypoplasia, stroke-like episodes, and retinitis pigmentosa in late infancy, childhood or adulthood.
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | ID_491821390 |
||
| English | Phosphomannomutase 2 deficiency |
Congenital disorder of glycosylation type 1a (CDG-Ia) is the most frequent form of CDG syndrome and is characterised by highly variable clinical manifestations that may include feeding problems, vomiting, and diarrhea with failure to thrive in infants, and severe encephalopathy with axial hypotonia, abnormal eye movement, marked psychomotor retardation, peripheral neuropathy, cerebellar hypoplasia, stroke-like episodes, and retinitis pigmentosa in late infancy, childhood or adulthood. |
Statements
CID11:ID_491821390
0 references
dki-india-ID_491821390
0 references
Concluído
0 references
15 August 2026
0 references
